soul trial oral semaglutide cardiovascular outcomes 2024 results Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study Trial Scorecard: SOUL

It is more common during the first two weeks and during dose escalation

The MHRA issued a Drug Safety Update in January 2025 about monitoring and managing gastrointestinal side effects with tirzepatide

Injections are given once per week, and your practitioner will normally start you at a lower dose, gradually increasing it as theyre able to monitor its effects and your progress

They include the weekly injectable drugs Zepbound (FDA approved for weight loss and sleep apnea) and Mounjaro (FDA approved for improving blood sugar levels in people with Type 2 diabetes, but often prescribed off-label for weight loss)

I proactively reduce doses and titrate using SMBG/CGM (ADA, 2024)